期刊文献+

复发转移乳腺癌患者血清HER2水平与组织表达状态的相关性 被引量:1

The Correlation between Serum HER2 Level and Expressions of HER2 in Tissues in Patients with Recurrent Metastatic Breast Cancer
下载PDF
导出
摘要 目的探讨复发转移乳腺癌患者血清HER2水平与组织表达状态间的联系,分析血清HER2检测是否可作为组织HER2检测的补充手段。方法采用酶联免疫吸附试验(ELISA)对72例女性复发转移乳腺癌(组织HER2阳性组30例,组织HER2阴性组42例)和30例健康体检女性(健康对照组)进行血清HER2水平检测,将各组的血清HER2水平进行比较,并与组织HER2表达状态进行对比分析。结果组织HER2阳性组的血清HER2水平显著高于组织HER2阴性组和健康对照组,差异有统计学意义(P<0.0001);组织HER2阴性组血清HER2水平与健康对照组比较差异无统计学意义(P=0.163);组织HER2阳性组有22例血清HER2阳性,阳性符合率为73.4%(22/30),组织HER2阴性组有32例血清HER2阴性,阴性符合率为78.6%(32/42)。血清HER2水平与组织HER2表达状态呈正相关(χ2=21.626,r=0.547)。结论血清HER2水平与组织HER2表达状态呈正相关,且血清HER2可以作为组织HER2检测的补充手段。 Objective To study the relationships between serum HER2 level and tissue HER2 status and analyze the possibility of serum HER2 being complementary to tissue HER2 detection in recurrent metastatic breast cancer patients.Methods 72 recurrent metastatic breast cancer patients(30 patients in tissue HER2-positive group,42 patients in tissue HER2-negative group) and 30 healthy women(healthy control group)were enrolled in the study,and the serum HER2 level were detected by ELISA and were compared with HER2 expression in tissues.Results The serum HER2 level was significantly higher in tissue HER2-positive group than in that in tissue HER2-negative group and healthy control group,and the differences were significant(P0.0001);there was no difference between tissue HER2-negative group and healthy control group(P=0.163);Serum HER2 was positive in 22 patients in tissue HER2-positive group and the positive accordance rate was 73.4%(22/33);Serum HER2 was positive in 22 patients in tissue HER2-negative group and the negative accordance rate was 78.6%(32/42).Serum HER2 was positively related to tissue HER2(χ2=21.626,r=0.547).Conclusion The serum HER2 is positively related to tissue HER2 status,which can be taken as a complementary method to tissue HER2 detection.
出处 《临床误诊误治》 2011年第10期4-7,共4页 Clinical Misdiagnosis & Mistherapy
关键词 肿瘤转移 复发 乳腺肿瘤 血清HER2 酶联免疫吸附测定 Metastatic breast cancer Recurrence Breast neoplasm Serum HER2 Enzyme-linked immunosorbent assay
  • 相关文献

参考文献9

  • 1Fehm T,Becker S,Duerr-Stoerzer S,et al.Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status[J].Breast Cancer Res,2007,9(5):74.
  • 2Locatelli M A,Curigliano G,Fumagalli L,et al.Should liver metastases of breast cancer be biopsied to improve treatment choice?[J].J Clin Oncol,2010,28 (18S):1008.
  • 3Carney W P,Neumann R,Lipton A,et al.Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer[J].Clin Chem,2003,49(10):1579-1598.
  • 4Zhang J Y,Mai G F,Zheng H,et al.Association between the survival time and high-expreasion of EGFR and HER-2in breast cancer[J].Di Yi Jun Yi Ds Xue Xue Bao,2003,23(10):1090-1092.
  • 5吴凡,叶韵斌,陆俐丽,陈强.乳腺癌患者血清HER2的检测及其临床意义[J].中国肿瘤生物治疗杂志,2009,16(4):405-409. 被引量:8
  • 6Schippinger W,Dandachi N,Regitnig P,et al.The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer[J].Am J Clin Pathol,2007,128 (4):630-637.
  • 7Kang S H,Cho J,Ha J S,et al.Evaluation of Serum HER-2/neu Extracelluar Domain in Breast Cancer Patients:Correlation with Tissue HER-2/neu Status and Clinicopathological Factors[J].JOURNAL OF THE KOREAN SURGICAL SOCIETY,2010,78(5):271-276.
  • 8廖天,陆云飞.乳腺癌患者血清HER2/neu水平与其组织HER2表达状态的关系[J].广西医科大学学报,2009,26(6):859-861. 被引量:4
  • 9鲁萍,张谷.荧光原位杂交技术检测乳腺癌HER-2基因扩增实验方法的比较[J].中华肿瘤防治杂志,2011,18(1):26-28. 被引量:9

二级参考文献29

  • 1PengYuan Bing-heXu Da-tongChu.CORRELATION BETWEEN SERUM HER-2 ONCOPROTEIN AND PATIENTS WITH BREAST CANCER[J].Chinese Medical Sciences Journal,2004,19(3):212-215. 被引量:8
  • 2Carney WP, Neumann R, Lipton A, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer [J]. Clin Chem, 2003 , 49(10) : 1579-1598.
  • 3Carney WP, Neumann R, Lipton A, et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer [ J ].Clin Breast Cancer, 2004, 5(2) : 105-116.
  • 4Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumabbased therapies [ J]. Breast Cancer Res, 2005, 7 (4) : R436- R443.
  • 5Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status [ J ]. Breast Cancer Res, 2007, 9 (5) : R74.
  • 6Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER- 2/neu status in a subset of distant metastases from breast carcinomas [J]. J Pathol, 2004, 203(4) : 918-926.
  • 7Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease [J]. Br J Cancer, 2005, 93(5) : 552-556.
  • 8Garoufali A, Kyriakou F, Kountourakis P, et al. Extracellular domain of HER2 : a useful marker for the initial workup and follow-up of HER2-positive breast cancer [J]. J BUON, 2008, 13 (3) : 409-413.
  • 9Fehm T, Jager W, Kraemer S, et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients [ J]. Anticancer Res, 2004 , 24(6) : 4205-4210.
  • 10Bramwell VH, Doig GS, Tuck AB, et al. Changes over time of extracellular domain of HER2 ( ECD/HER2 ) serum levels have prognostic value in metastatic breast cancer [ J]. Breast Cancer Res Treat, 2009, 114(3) : 503-511.

共引文献17

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部